A. Bodmer

Discipline

Economies et finances (1)

Type de document

Articles (8) Colloques et conférences (2) Recensions (1)

Co-auteur

Date

Source

Mot-clé

Treatment (9) cancer (8) Cancer (8) Patients (8) Cancer (8) Patients (8) thérapie (6) Chemotherapy (6) Therapeutics (6) Chemotherapy (6) Human beings (5) Breast (5) norme (3) oncologie (3) abords (agglomération) (3) survie (3) Case (3) Methods (3) Women (3) Ci (Chinese poetry) (3) Survival (3) Oncology (3) Months (3) Grammar, Comparative and general--Case (3) Evidence (3) Cells (3) Case (3) Methods (3) Use (3) Women (3)

Documents écrit par A. Bodmer (10) | parle de A. Bodmer (0)

Le régime cétogène : efficace contre le cancer ? [Is ketogenic diet effective against cancer ?]
A.T. Tankeu et al. (22 mars 2023)
A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer.
C. Mamot et al. (6 mars 2023)
Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab.
L. Thouvenin et al.
Gestational trophoblastic disease in Switzerland: retrospective study of the impact of a regional reference centre.
A. Fehlmann et al. (1 févr. 2021)
Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss.
D. Frisone et al. (2020)
Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor.
K. Ahmed et al. (1 mai 2019)
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.
H. Bonnefoi et al. (2014)
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
A.F. Hottinger et al. (2014)
Breast cancer incidence in younger swiss women
A. Bodmer et al. (2013)
Prospective assessment of CYP2D6 by genotyping, phenotyping and measurement of tamoxifen, PD 05-09 4-hydroxy-tamoxifen and endoxifen in breast cancer patients treated with tamoxifen.
K. Zaman et al. (2010)